The Memory Disorders Program is conducting the following ongoing clinical trials. These trials are underway and are no longer recruiting participants.
| Status | Title | Trial Information | Sponsor |
|---|---|---|---|
| Ongoing | ADNI: Alzheimer's Disease Neuroimaging Initiative | Trial | National Institute on Aging (NIA) National Institute for Biomedical Imaging and Bioengineering (NIBIB) Foundation for the National Institutes of Health Alzheimer's Drug Discovery Foundation Alzheimer's Association |
| Ongoing | DHA (Docosahexaenoic Acid), an Omega 3 Fatty Acid, in Slowing the Progression of Alzheimer's Disease | Trial | National Institute on Aging (NIA) Martek Biosciences Corporation |
| Ongoing | AAB-001 (Bapineuzumab) Open-Label, Long-Term Extension Study in Patients With Mild to Moderate Alzheimer's Disease | Trial | Elan Pharmaceuticals |
| Ongoing | ELND005 in Patients With Mild to Moderate Alzheimer's Disease | Trial | Elan Pharmaceuticals |
| Ongoing | A Phase 2 Study Evaluating The Efficacy And Safety Of PF 04494700 In Mild To Moderate Alzheimer's Disease | Trial | Pfizer/Alzheimer's Disease Cooperative Studies (ADCS) |
| Ongoing | Home-Based Assessment for Alzheimer's Disease Prevention (HBA) | Trial | National Institute on Aging/Alzheimer's Disease Cooperative Trial |
| Ongoing | Effect of LY450139 on the Long Term Progression of Alzheimer's Disease | Trial | Eli Lilly & Company |